← Back to Search

Monoclonal Antibodies

IMC-002 for Lymphoma

Phase 1
Waitlist Available
Research Sponsored by ImmuneOncia Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new drug (IMC-002) to see if it is safe and effective in treating subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas.

Eligible Conditions
  • Lymphoma
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of adverse events (AEs)
Occurrence of dose-limiting toxicities (DLT)

Trial Design

1Treatment groups
Experimental Treatment
Group I: IMC-002Experimental Treatment1 Intervention
Dose escalation will follow the traditional 3+3 design.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMC-002
2020
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

ImmuneOncia Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
117 Total Patients Enrolled
1 Trials studying Lymphoma
23 Patients Enrolled for Lymphoma
HEUNG TAE KIMStudy DirectorImmuneOncia Therapeutics Inc.
Ji Hye LeeStudy DirectorImmuneOncia Therapeutics Inc.
1 Previous Clinical Trials
23 Total Patients Enrolled
1 Trials studying Lymphoma
23 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
2020. "A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04306224.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top